Grass pollen allergoid. A 4-year follow-up study.
In an open comparative study with 31 grass pollen-allergic patients, two allergen extracts ('allergoid' extract/semi-depot extract) were examined. In the 1st year of treatment the allergoid group showed better results in relation to symptom score, drug consumption and IgG response, however, in the course of further treatment this difference was not evident anymore. Treatment was successful in both groups. A significant correlation between total antigen dose and IgG response was found. The better clinical results for the allergoid group in the first season after the 1st and 4th year of observation do indicate a better long-term therapeutic effect compared to the semi-depot group. This finding probably is due to the much higher antigen dose (4-fold) in the allergoid group.
D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology; D000080384:Allergoids; D000917:Antibody Formation; D005500:Follow-Up Studies; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D007073:Immunoglobulin E / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D010936:Plant Extracts / Q000276:immunology / Q000627:therapeutic use*; D011058:Pollen / Q000276:immunology*; D012621:Seasons; D013997:Time Factors
D000485:Allergens; D000080384:Allergoids; D007074:Immunoglobulin G; D010936:Plant Extracts; D007073:Immunoglobulin E